Inmune Bio (INMB) Return on Sales (2021 - 2025)
Inmune Bio (INMB) posted Return on Sales of 11.73% for Q4 2025, up 7.09% sequentially from 12.63% in Q3 2025, and up 14765.0% YoY from N/an in Q4 2024.
Inmune Bio (INMB) Return on Sales (2021 - 2025) Analysis & Trends
Inmune Bio has reported Return on Sales for 5 years, with the latest figure at 11.73% in Q4 2025.
- Quarterly Return on Sales rose 14765.0% year-over-year to 11.73% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 11.73% (up 14765.0% YoY) and the FY2025 annual result came in at 16.42%, up 3238.0% from the prior year.
- Return on Sales advanced to 11.73% in Q4 2025 per INMB's latest filing, from 12.63% in the prior quarter.
- Over five years, Return on Sales peaked at 0.42% in Q1 2022 and troughed at 249.44% in Q2 2021.
- A 5-year average of 36.94% and a median of 10.46% in 2024 frame the typical range for Return on Sales.
- The sharpest annual moves came in 2022 and 2024: Return on Sales jumped 24516 bps in 2022, then tumbled 15607 bps in 2024.
- Over 5 years, Return on Sales stood at 0.58% in 2021, then declined by 15 bps to 0.67% in 2022, then plunged by 394 bps to 3.31% in 2023, then plunged by 4718 bps to 159.38% in 2024, then jumped by 93 bps to 11.73% in 2025.
- According to Business Quant data, Return on Sales over the past three periods registered 11.73%, 12.63%, and 42.36% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 0.00% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -0.05% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 0.00% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 0.00% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 0.00% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 0.00% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 0.00% |
| 10 | Inmune Bio | 61.59 Mn | 43.18 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -11.73% |
| Sep 30, 2025 | -12.63% |
| Jun 30, 2025 | -42.36% |
| Mar 31, 2025 | -3.86% |
| Dec 31, 2024 | -159.38% |
| Sep 30, 2024 | -52.83% |
| Jun 30, 2024 | -9.18% |
| Mar 31, 2024 | -24.88% |
| Dec 31, 2023 | -3.31% |
| Sep 30, 2023 | -3.12% |
| Jun 30, 2023 | -1.53% |
| Mar 31, 2023 | -1.85% |
| Dec 31, 2022 | -0.67% |
| Sep 30, 2022 | -54.33% |
| Jun 30, 2022 | -4.28% |
| Mar 31, 2022 | -0.42% |
| Dec 31, 2021 | -0.58% |
| Sep 30, 2021 | -38.71% |
| Jun 30, 2021 | -249.44% |
| Mar 31, 2021 | -63.73% |